VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Vistagen Therapeutics, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.20+0.00 (+1.55%)
Close on Oct 19, 2026
- Market cap
- $8.73M
- P/E (TTM)
- –
- Dividend yield
- –
Vistagen Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q3 24 | Q2 24 | Q4 23 | Q3 23 | Q2 23 | Q1 23 | Q4 22 | Q3 22 | Q2 22 | Q1 22 | Q3 21 | Q2 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sublicense [Member] | $400.00K | $277.70K | – | – | – | – | – | – | – | – | – | – | 97.3% | – |
| License | – | – | $176.00K | $180.00K | -$893.00K | $310.00K | $39.00K | $358.00K | $358.00K | $354.00K | $313.60K | $334.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Vistagen Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.